FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807160230> ?p ?o ?g. }

• W2807160230 endingPage "59" @default.
• W2807160230 startingPage "48" @default.
• W2807160230 abstract "Advances in the Management of Triple Negative Breast Cancer Role of metabolic rehabilitation-based approach in TNBC: biguanide metformin and moreLev M Berstein, , Garik A Dashyan & Vladimir F SemiglazovLev M BersteinDr Lev M Berstein is Chief of Laboratory of Oncoendocrinology at Petrov Research Institute of Oncology, St Petersburg, Russia. His main scientific interests include mechanisms of hormonal carcinogenesis, risk factors and approaches to prevention and treatment of hormone-associated tumors. He received several international distinctions (including INTAS grant and UICC Translational Cancer Research Fellowship), and serves as a Member of Council of Russian Endocrine Association, on the editorial boards of several peer-reviewed journals in cancer and endocrinology areas and as a reviewer for a number of well-known journals in these fields. In his bibliography are ten monographs, approximately 20 chapters and more than 150 papers. He graduated as MD from Tartu University in Estonia and received his PhD and DMS degrees in Cancer Endocrinology at the Petrov Institute in St Petersburg.Search for more papers by this author, , Garik A DashyanDr Garik A Dashyan is Senior Scientific Associate of the NN Petrov Research Institute of Oncology (St Petersburg, Russia). His main areas of scientific research are the optimization of local and systemic treatment of breast cancer, pregnancy-associated cancer. He is the author of more than 50 scientific publications.Search for more papers by this author & Vladimir F SemiglazovVladimir F Semiglazov is Doctor of Sciences, Corresponding Member of the Russian Academy of Medical Sciences. His main spheres of scientific research are pathogenesis of tumors, organization of clinical trials, and accomplishment of methods of surgical treatment of cancer, neoadjuvant and adjuvant systemic treatment of breast cancer. He is the author of more than 350 publications, including seven monographs.Search for more papers by this authorPublished Online:25 Oct 2011https://doi.org/10.2217/ebo.11.2AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit View chapterAbstract: Triple-negative breast cancer (TNBC) presents one of the subtypes of breast cancer and is characterized with aggressive clinical course and close to complete insensibility to endocrine therapy. The aim of this chapter is to briefly characterize hormonal and metabolic features unique to TNBC, which together with some general rationales call for the usage of the metabolic rehabilitation approach in these circumstances. Metabolic rehabilitation is considered to be an important reserve in the prevention and treatment of mammary carcinomas, including TNBC. Bibliography1 Cianfrocca M , Gradishar W . New molecular classifications of breast cancer . CA Cancer J. Clin. . 59 (5) , 303 – 313 (2009) . Crossref, Medline, Google Scholar2 Kwan ML , Kushi LH , Weltzien E et al. . Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors . Breast Cancer Res . 11 (3) , R31 (2009) . Crossref, Medline, Google Scholar3 Yang XR , Chang-Claude J , Goode EL . et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies . J. Natl Cancer Inst . 103 (3) , 250 – 263 (2011) . Crossref, Medline, Google Scholar4 Millikan RC , Newman B , Tse CK et al. Epidemiology of basal-like breast cancer . Breast Cancer Res. Treat . 109 (1) , 123 – 139 (2008) . Crossref, Medline, Google Scholar5 Maiti B , Kundranda MN , Spiro TP , Daw HA . The association of metabolic syndrome with triple-negative breast cancer . Breast Cancer Res. Treat. 121 (2) , 479 – 483 (2010) . Crossref, Medline, CAS, Google Scholar6 Brunet J , Vazquez-Martin A , Colomer R , Graña-Suarez B , Martin-Castillo B , Menendez JA . BRCA1 and acetyl-CoA carboxylase: The metabolic syndrome of breast cancer . Mol. Carcinog . 47 (2) , 157 – 163 (2008) . Crossref, Medline, CAS, Google Scholar7 Berstein LM . Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis . Future Oncol . 4 (1) , 23 – 39 (2008) . Link, CAS, Google Scholar8 Goodwin PJ , Ennis M , Bahl M et al. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome . Breast Cancer Res. Treat. 114 (3) , 517 – 525 (2009) . Crossref, Medline, CAS, Google Scholar9 Dilman VM , Berstein LM , Yevtushenko TP et al. Preliminary evidence on metabolic rehabilitation of cancer patients . Arch. Geschwulstforsch . 58 (3) , 175 – 183 (1988) . Medline, CAS, Google Scholar10 Berstein LM . Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond . Future Oncol . 6 (8) , 1313 – 1323 (2010) . Link, CAS, Google Scholar11 Semiglazov VF , Semiglazov VV , Dashyan GA et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer . Cancer 110 (2) , 244 – 254 (2007) . Crossref, Medline, CAS, Google Scholar12 Yagata H , Kajiura Y , Yamauchi H . Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy . Breast Cancer DOI: 10.1007/s12282-011-0254-9 (2011) (Epub ahead of print). Google Scholar13 Alexander BM , Sprott K , Farrow DA . et al. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer . Clin. Cancer Res. 16 (23) , 5796 – 5804 (2010) . Crossref, Medline, CAS, Google Scholar14 De Berardinisa RJ , Lum JJ , Hatzivassiliou G , Thompson CB . The biology of cancer: metabolic reprogramming fuels cell growth and proliferation . Cell Metab. 7 (1) , 11 – 20 (2008) . Crossref, Medline, Google Scholar15 Perou CM . Molecular stratification of triple-negative breast cancers . Oncologist 16 (Suppl. 1) , 61 – 70 (2011) . Crossref, Medline, Google Scholar16 Hirsch HA , Iliopoulos D , Tsichlis PN , Struhl K . Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission . Cancer Res. 69, 7507–7511 (2009) . Crossref, Medline, CAS, Google Scholar17 Shu Y , Brown C , Castro RA et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics . Clin. Pharmacol. Ther. 83 (2) , 273 – 280 (2008) . Crossref, Medline, CAS, Google Scholar18 Pollak M . Insulin and insulin-like growth factor signalling in neoplasia . Nat. Rev. Cancer 8 (12) , 915 – 928 (2008) . Crossref, Medline, CAS, Google Scholar19 Dowling RJ , Zakikhani M , Fantus IG, Pollak M , Sonenberg N . Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells . Cancer Res. 67, 10804–10812 (2007) . Medline, Google Scholar20 Garwood ER , Kumar AS , Baehner FL et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer . Breast Cancer Res. Treat. . 119 , 137 – 144 (2010) . Crossref, Medline, CAS, Google Scholar21 Liu B , Fan Z , Edgerton SM et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells . Cell Cycle 8 (13) , 2031 – 2040 (2009) . Crossref, Medline, CAS, Google Scholar22 Vazquez-Martin A , Oliveras-Ferraros C , Cufí S . et al. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells . Oncol. Rep. 25 (1) , 135 – 140 (2011) . Medline, CAS, Google Scholar23 Jiralerspong S , Gonzalez-Angulo AM , Hung MC . Expanding the arsenal: metformin for the treatment of triple-negative breast cancer? Cell Cycle 8 (17) , 2681 (2009) . Medline, Google Scholar24 Dowling RJ , Goodwin PJ , Stambolic V . Understanding the benefit of metformin use in cancer treatment . BMC Med. 9 (1) , 33 (2011) . Crossref, Medline, CAS, Google Scholar25 Cuzick J , Decensi A , Arun B . et al. Preventive therapy for breast cancer: a consensus statement . Lancet Oncol. 12 (5) , 496 – 503 (2011) . Crossref, Medline, CAS, Google ScholarWebsites101 Metabolic syndrome http://en.wikipedia.org/wiki/metabolic_syndromeGoogle Scholar102 Molecular subtypes of breast cancer – Susan G Komen for the cure ww5.komen.org/breastcancer/subtypesofbreastcancer.htmlGoogle Scholar103 Metformin and cancer www.cancer.gov/clinicaltrialsGoogle ScholarFiguresReferencesRelatedDetails Advances in the Management of Triple Negative Breast CancerMetrics Downloaded 17 times History Published online 25 October 2011 Published in print October 2011 Information© Future Medicine Ltd© 2011 Future Medicine LtdPDF download" @default.
• W2807160230 created "2018-06-13" @default.
• W2807160230 creator A5012274064 @default.
• W2807160230 creator A5021151348 @default.
• W2807160230 creator A5068100907 @default.
• W2807160230 date "2011-10-01" @default.
• W2807160230 modified "2023-09-23" @default.
• W2807160230 title "Role of metabolic rehabilitation-based approach in TNBC: biguanide metformin and more" @default.
• W2807160230 cites W2012902516 @default.
• W2807160230 cites W2014058353 @default.
• W2807160230 cites W2017047594 @default.
• W2807160230 cites W2026880258 @default.
• W2807160230 cites W2034843329 @default.
• W2807160230 cites W2042008937 @default.
• W2807160230 cites W2058585724 @default.
• W2807160230 cites W2080204015 @default.
• W2807160230 cites W2086818413 @default.
• W2807160230 cites W2089171551 @default.
• W2807160230 cites W2102257452 @default.
• W2807160230 cites W2106663556 @default.
• W2807160230 cites W2108183713 @default.
• W2807160230 cites W2109535392 @default.
• W2807160230 cites W2113633750 @default.
• W2807160230 cites W2122889158 @default.
• W2807160230 cites W2125747634 @default.
• W2807160230 cites W2130592216 @default.
• W2807160230 cites W2141868357 @default.
• W2807160230 cites W2155533563 @default.
• W2807160230 doi "https://doi.org/10.2217/ebo.11.2" @default.
• W2807160230 hasPublicationYear "2011" @default.
• W2807160230 type Work @default.
• W2807160230 sameAs 2807160230 @default.
• W2807160230 citedByCount "0" @default.
• W2807160230 crossrefType "other" @default.
• W2807160230 hasAuthorship W2807160230A5012274064 @default.
• W2807160230 hasAuthorship W2807160230A5021151348 @default.
• W2807160230 hasAuthorship W2807160230A5068100907 @default.
• W2807160230 hasConcept C134018914 @default.
• W2807160230 hasConcept C185592680 @default.
• W2807160230 hasConcept C1862650 @default.
• W2807160230 hasConcept C2777688063 @default.
• W2807160230 hasConcept C2778818304 @default.
• W2807160230 hasConcept C2780323712 @default.
• W2807160230 hasConcept C555293320 @default.
• W2807160230 hasConcept C71924100 @default.
• W2807160230 hasConceptScore W2807160230C134018914 @default.
• W2807160230 hasConceptScore W2807160230C185592680 @default.
• W2807160230 hasConceptScore W2807160230C1862650 @default.
• W2807160230 hasConceptScore W2807160230C2777688063 @default.
• W2807160230 hasConceptScore W2807160230C2778818304 @default.
• W2807160230 hasConceptScore W2807160230C2780323712 @default.
• W2807160230 hasConceptScore W2807160230C555293320 @default.
• W2807160230 hasConceptScore W2807160230C71924100 @default.
• W2807160230 hasLocation W28071602301 @default.
• W2807160230 hasOpenAccess W2807160230 @default.
• W2807160230 hasPrimaryLocation W28071602301 @default.
• W2807160230 hasRelatedWork W183173152 @default.
• W2807160230 hasRelatedWork W2001497361 @default.
• W2807160230 hasRelatedWork W2167556067 @default.
• W2807160230 hasRelatedWork W2382018013 @default.
• W2807160230 hasRelatedWork W2888022043 @default.
• W2807160230 hasRelatedWork W3000483898 @default.
• W2807160230 hasRelatedWork W3094613791 @default.
• W2807160230 hasRelatedWork W4206030171 @default.
• W2807160230 hasRelatedWork W4233459720 @default.
• W2807160230 hasRelatedWork W86099048 @default.
• W2807160230 isParatext "false" @default.
• W2807160230 isRetracted "false" @default.
• W2807160230 magId "2807160230" @default.
• W2807160230 workType "other" @default.